Provided by Tiger Trade Technology Pte. Ltd.

BioVie Inc

1.95
+0.09004.84%
Post-market: 1.960.0100+0.51%19:59 EDT
Volume:19.76M
Turnover:43.11M
Market Cap:16.48M
PE:-0.64
High:2.48
Open:2.16
Low:1.80
Close:1.86
52wk High:3.79
52wk Low:0.8200
Shares:8.45M
Float Shares:8.41M
Volume Ratio:0.92
T/O Rate:235.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0500
EPS(LYR):-3.0500
ROE:-150.76%
ROA:-79.06%
PB:1.60
PE(LYR):-0.64

Loading ...

BioVie completes enrollment in Phase 2 long COVID trial of bezisterim, targets late summer 2026 data

Reuters
·
May 26

BioVie Announces Full Enrollment of the Address-Lc Trial of Bezisterim for the Treatment of Neurological Symptoms Associated With Long Covid

THOMSON REUTERS
·
May 26

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

GlobeNewswire
·
May 26

BioVie Announces Completion of Phase 2 Sunrise-Pd Trial in Early-Stage Parkinson’s Disease

THOMSON REUTERS
·
May 18

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease

GlobeNewswire
·
May 18

BioVie Q3 FY26 net loss widens to $5.3 million; operating expenses climb to $5.4 million

Reuters
·
May 12

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

GlobeNewswire
·
Apr 27

BioVie SUNRISE-PD bezisterim abstract accepted for presentation at 2026 AAN meeting

Reuters
·
Apr 14

BioVie publishes corporate presentation on bezisterim pipeline catalysts in Parkinson’s, Long Covid

Reuters
·
Apr 02

BioVie to present SUNRISE-PD bezisterim poster at AD/PD 2026

Reuters
·
Mar 12

BioVie Announces Abstract Accepted for Presentation at AD/PD 2026

GlobeNewswire
·
Mar 12

BioVie to Host Live Investor Webinar and Q&A Session with CEO Cuong Do

Reuters
·
Feb 23

Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4

GlobeNewswire
·
Feb 23